Kadmon Holdings Inc (NASDAQ:KDMN) was downgraded by equities researchers at WBB Securities from a “hold” rating to a “sell” rating in a research note issued to investors on Monday. They presently have a $3.00 price objective on the stock. WBB Securities’ price objective would suggest a potential downside of 18.48% from the stock’s current price.

KDMN has been the subject of several other research reports. ValuEngine lowered Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies set a $7.00 target price on Kadmon Holdings and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Kadmon Holdings in a research report on Monday, June 26th. Finally, Zacks Investment Research lowered Kadmon Holdings from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $9.80.

Shares of Kadmon Holdings (KDMN) opened at 3.68 on Monday. Kadmon Holdings has a 52 week low of $2.86 and a 52 week high of $7.10. The firm’s market cap is $190.79 million. The firm has a 50-day moving average price of $3.41 and a 200-day moving average price of $3.41.

Kadmon Holdings (NASDAQ:KDMN) last announced its earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.05. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.46 million. During the same period in the prior year, the company posted ($4.40) EPS. The firm’s revenue was down 53.1% on a year-over-year basis. On average, equities research analysts predict that Kadmon Holdings will post ($1.54) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/11/kadmon-holdings-inc-kdmn-stock-rating-lowered-by-wbb-securities.html.

In related news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $2.73, for a total value of $827,053.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 14,707 shares of company stock worth $34,294 in the last 90 days.

Several institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its stake in shares of Kadmon Holdings by 134.7% in the 1st quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock worth $18,772,000 after buying an additional 2,976,190 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Kadmon Holdings by 166.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after buying an additional 941,549 shares during the last quarter. Sabby Management LLC purchased a new stake in shares of Kadmon Holdings in the 2nd quarter worth approximately $2,112,000. JPMorgan Chase & Co. grew its stake in shares of Kadmon Holdings by 11,654.8% in the 1st quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock worth $829,000 after buying an additional 226,919 shares during the last quarter. Finally, Sawtooth Solutions LLC grew its stake in shares of Kadmon Holdings by 396.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 99,649 shares of the company’s stock worth $388,000 after buying an additional 79,593 shares during the last quarter.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Analyst Recommendations for Kadmon Holdings (NASDAQ:KDMN)

Receive News & Stock Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related stocks with our FREE daily email newsletter.